Clobazam in Treatment of Refractory Epilepsy: The Canadian Experience. A Retrospecti

@article{1991ClobazamIT,
  title={Clobazam in Treatment of Refractory Epilepsy: The Canadian Experience. A Retrospecti},
  author={},
  journal={Epilepsia},
  year={1991},
  volume={32}
}
  • Published 1 June 1991
  • Medicine
  • Epilepsia
Summary: During the past 7 years in Canada, more than 1,300 refractory epileptic patients have been treated with clobazam (CLB) by 104 adult and pediatric neurologists. Using a standard case report, 32 neurologists, who had each treated ≫ 10 patients, provided retrospective data for 877 patients. The population had the following characteristics: the percentages of children and adults were 51 and 49%, respectively; 38% of the patients were mentally retarded; the percentages for single and… 

Clobazam as Add-on Therapy in Children with Epileptic Encephalopathy

Clobazam is safe and effective in the treatment of epileptic encephalopathies of childhood, and in 85% of the patients with seizure improvement, the results lasted for more than one year.

Long-Term Use of Clobazam in Lennox-Gastaut Syndrome: Experience in a Single Tertiary Epilepsy Center

Clobazam add-on therapy was effective and very tolerable in patients with Lennox-Gastaut syndrome and was not significantly associated with age, sex, or etiology.

Efficacy of Clobazam as Add-on Therapy for Refractory Epilepsy: Experience at a US Epilepsy Center

In this population of patients with highly refractory epilepsy seen at a tertiary US center, 11% of patients became seizure-free for at least 6 months after addition of CLB, and the 1-year retention rate was 61%.

Effectiveness of clobazam as add-on therapy in children with refractory focal epilepsy.

Clobazam seems to be safe and effective in the treatment of focal epilepsy in childhood and should be considered in patients with refractory seizures.

Effect of clobazam as add-on antiepileptic drug in patients with epilepsy

Evaluating usage pattern, retention rate, effectiveness and tolerability of clobazam during routine practice in an outpatient epilepsy clinic of a tertiary care hospital in New Delhi, India provides valuable information about the clinical use of clOBazam as add-on antiepileptic drug therapy in the management of patients with epilepsy.

Clobazam

This review will explore the use of clobazam in the treatment of epilepsy, particularly with regard to its potential benefit in Lennox-Gastaut syndrome.

Clobazam as Add-on Therapy for Temporal Lobe Epilepsy and Hippocampal Sclerosis

The data suggest that clobazam should be considered as add-on therapy in the treatment of patients with temporal lobe epilepsy associated with MRI signs of HS.

Clobazam Efficacy as an Add-on Therapy for 121 Patients with Intractable Epilepsy

Clobazam efficacy more superior in generalized seizures type i.e. myoclonic, atonic, infantile spasm more than generalized tonic clonic and partial seizures and younger children response better than older children.

CLB add-on treatment in patients with epileptic encephalopathy: a single center experience with long-term follow-up

Clobazam should be considered as an optional antiepileptic that is well tolerated, particularly in EEs with myoclonic andMyoclonic-atonic/atonic seizures, particularly at first year of treatment in comparison to basal EEG findings.
...

References

SHOWING 1-10 OF 23 REFERENCES

Clobazam for refractory focal epilepsy. A controlled trial.

Tolerance to the antiepileptic effect of clobazam was noted in 56% of the patients, and mild transient sedation occurred in 40% ofThe number of seizures was lower during the three months of active treatment, and clobzam is an effective add-on drug for individual patients with refractory focal epilepsy.

Clobazam as adjunctive treatment in refractory epilepsy.

Repeat intravenous urography after five years confirmed the normality of the kidneys, and analysis of urine gave consistently normal results, and plasma urea and creatinine concentrations were within normal ranges.

Clobazam for refractory epilepsy.

The question posed by Schmidt et al 1 as a result of their study, ie, the need to identify and select those patients who are likely to obtain sustained dramatic benefit from clobazam therapy, was attempted.

Current Status of the 1,4‐ and 1,5‐Benzodiazepines in the Treatment of Epilepsy: The Place of Clobazam

The main disadvantage of clobazam is the development of tolerance, which develops in approximately 36% of patients, and there is no way of predicting in which patients or when the phenomenon is likely to occur, so a dose of 20 to 30 mg at night is recommended, possibly commencing at 10 mg.

Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures.

Overall, carbamazepine and phenytoin are recommended drugs of first choice for single-drug therapy of adults with partial or generalized tonic-clonic seizures or with both.

The Risk-Benefit Ratio of Anticonvulsant Drugs

  • M. Eadie
  • Medicine
    Medical toxicology and adverse drug experience
  • 1987
To provide optimal management for individual patients, the risk-benefit ratio of therapy must be repeatedly assessed at all stages of a patient’s treatment, and therapeutic decisions taken in the light of the ratio as it applies to the individual.

Comparative Anticonvulsant Activity and Neurotoxicity of Clobazam, Diazepam, Phenobarbital, and Valproate in Mice and Rats

The results obtained indicate that clobazam and valproate exhibit a wider range of experimental anticonvulsant activity than either diazepam or phenobarbital, and suggest that the spectrum of anticonventricular activity for the 1,5‐benzodiazepine (clobazem) is superior to that for the1,4‐benZodiazepines (diazepam).

Pharmacology of anti-anxiety drugs with special reference to clobazam.

The advantage of clobazam compared with the 1.4 benzodiazepines lies mainly in the fact that motor activity is influenced only after very high doses, these doses being markedly above those required to induce tranquillizing and anti-agression activities.